U.S. regulators on Thursday approved a new kind of cancer drug from Merck & Co. that is designed to unleash the body's immune system against tumors. The drug is part of a long-anticipated wave of medicines that could transform cancer treatment and forge a large new market for pharmaceutical companies.. The Food and Drug Administration cleared the drug, pembrolizumab, for the treatment of a deadly form of skin cancer, melanoma. The approval followed a swift review of data from a relatively early-stage human trial—an unusual...
  